Digital pathology firm Diagnexia and Stratipath AB, a pioneer in AI-based cancer diagnostics, have announced a strategic partnership to bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.
By integrating Stratipath’s AI-based technology into Diagnexia’s digital pathology network, the partnership will enable faster, more precise, and cost-effective cancer diagnostics, benefiting both clinicians and patients by enabling faster, more precise treatment decisions.
Stratipath Breast is an AI-based prognostic tool that analyses routine H&E-stained histopathology images to classify breast cancer tumours into high- and low-risk categories. The solution is compliant for clinical use in the EU and UK (CE-IVD and UK Rep), and is already in clinical use in several hospitals. This approach provides rapid and actionable insights, enabling oncologists and pathologists to accelerate decision-making by delivering results in under an hour (compared to up to two weeks for gene expression tests) while reducing costs.
While gene expression tests provide valuable insights for treatment decisions, their high costs, lengthy turnaround times, and complex handling limit accessibility and contribute to unequal access to precision diagnostics. Stratipath Breast simplifies this process by analysing routine pathology H+E slides already in the diagnostic workflow. With no additional investment or manual handling required, it enables faster, more efficient, and equitable access to precision diagnostics.
As a leader in digital and computational pathology, Diagnexia connects a global network of subspecialty pathologists with hospitals and laboratories. This partnership aligns with Diagnexia’s mission to enhance diagnostic efficiency, accuracy, and accessibility through cutting-edge AI tools.
Donal O'Shea, CEO of Diagnexia commented: “Stratipath Breast is a natural addition to our portfolio of AI-Based digital pathology solutions. At Diagnexia, we are committed to advancing precision oncology by integrating AI into routine clinical workflows. This partnership allows us to bring Stratipath’s groundbreaking risk stratification technology to more patients and clinicians, reducing delays and improving access to personalised cancer diagnostics.”